Literature DB >> 21142860

Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy.

Jesse D Martinez1.   

Abstract

Loss of p53 tumor suppressor function is a key event in the genesis of most human tumors. This observation has prompted efforts to restore p53 activity as an anticancer therapeutic approach. Recent developments that have extended our understanding of how p53 activity is regulated and how mutations disrupt that regulation have provided the insight needed to develop therapeutic strategies that take advantage of this knowledge. In this article, we review the strategies for restoring p53 function and some of the new compounds that show promise as antitumor agents in preclinical models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21142860      PMCID: PMC3039681          DOI: 10.2217/fon.10.132

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  44 in total

Review 1.  Extending nature's leads: the anticancer agent ellipticine.

Authors:  Nichola C Garbett; David E Graves
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-03

2.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

Review 3.  The ASPP family: deciding between life and death after DNA damage.

Authors:  Elizabeth A Slee; Xin Lu
Journal:  Toxicol Lett       Date:  2003-04-04       Impact factor: 4.372

4.  Presence of a potent transcription activating sequence in the p53 protein.

Authors:  S Fields; S K Jang
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

Review 5.  Mdm2-mediated ubiquitylation: p53 and beyond.

Authors:  J-C Marine; G Lozano
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

6.  Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics.

Authors:  Lyubomir T Vassilev
Journal:  Cell Cycle       Date:  2004-04-01       Impact factor: 4.534

7.  ASPP1 and ASPP2: common activators of p53 family members.

Authors:  Daniele Bergamaschi; Yardena Samuels; Boquan Jin; Sai Duraisingham; Tim Crook; Xin Lu
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

8.  Oligodendrocyte injury in multiple sclerosis: a role for p53.

Authors:  Karolina Wosik; Jack Antel; Tanja Kuhlmann; Wolfgang Brück; Bernard Massie; Josephine Nalbantoglu
Journal:  J Neurochem       Date:  2003-05       Impact factor: 5.372

Review 9.  p53 family members and chemoresistance in cancer: what we know and what we need to know.

Authors:  Milena Gasco; Tim Crook
Journal:  Drug Resist Updat       Date:  2003-12       Impact factor: 18.500

10.  PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.

Authors:  Jeremy M R Lambert; Petr Gorzov; Dimitry B Veprintsev; Maja Söderqvist; Dan Segerbäck; Jan Bergman; Alan R Fersht; Pierre Hainaut; Klas G Wiman; Vladimir J N Bykov
Journal:  Cancer Cell       Date:  2009-05-05       Impact factor: 31.743

View more
  8 in total

Review 1.  Multiple functions of p21 in cancer radiotherapy.

Authors:  Yanbei Kuang; Jian Kang; Hongbin Li; Bingtao Liu; Xueshan Zhao; Linying Li; Xiaodong Jin; Qiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

2.  Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status.

Authors:  Vlad C Sandulache; Heath D Skinner; Thomas J Ow; Aijun Zhang; Xuefeng Xia; James M Luchak; Lee-Jun C Wong; Curtis R Pickering; Ge Zhou; Jeffrey N Myers
Journal:  Cancer       Date:  2011-06-30       Impact factor: 6.860

3.  The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma.

Authors:  Yanli Luo; Ling Tian; Ye Feng; Miaoying Yi; Xiafang Chen; Qian Huang
Journal:  Pathol Oncol Res       Date:  2012-07-11       Impact factor: 3.201

Review 4.  Modulation of p53 during bacterial infections.

Authors:  Christine Siegl; Thomas Rudel
Journal:  Nat Rev Microbiol       Date:  2015-11-09       Impact factor: 60.633

5.  Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.

Authors:  Zhenghu Chen; Long Wang; Dayong Yao; Tianshu Yang; Wen-Ming Cao; Jun Dou; Jonathan C Pang; Shan Guan; Huiyuan Zhang; Yang Yu; Yanling Zhao; Yongfeng Wang; Xin Xu; Yan Shi; Roma Patel; Hong Zhang; Sanjeev A Vasudevan; Shangfeng Liu; Jianhua Yang; Jed G Nuchtern
Journal:  Sci Rep       Date:  2016-12-19       Impact factor: 4.379

6.  Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.

Authors:  Mariia Patyka; Zeinab Sharifi; Kevin Petrecca; Jose Mansure; Bertrand Jean-Claude; Siham Sabri
Journal:  Oncotarget       Date:  2016-09-13

Review 7.  A journey under the sea: the quest for marine anti-cancer alkaloids.

Authors:  Rita Tohme; Nadine Darwiche; Hala Gali-Muhtasib
Journal:  Molecules       Date:  2011-11-23       Impact factor: 4.411

Review 8.  The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy.

Authors:  Nina-Naomi Kreis; Frank Louwen; Juping Yuan
Journal:  Cancers (Basel)       Date:  2019-08-21       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.